DGIdb - ABEMACICLIB Drug Record

ABEMACICLIB chembl:CHEMBL3301610 ApprovedAntineoplastic

Alternate Names:

VERZENIO
ABEMACICLIB
VERZENIOS
LY-2835219
HY-16297A
LY2835219
CS-1230
LY 2835219
chembl:CHEMBL3301610
pubchem.compound:46220502
chemidplus:1231929-97-7
drugbank:12001

Drug Info:

Pharmaceutical Developer	Eli Lilly
Source Reported Drug Name(s)	LY2835219
Drug Class	CDK/Rb Inhibitor

(6 More Sources)

Publications:

von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.
Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
Gelbert et al., 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine., Invest New Drugs
Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun
Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun

ABEMACICLIB CCND2

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
ABEMACICLIB SMARCA4

Interaction Score: 1.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30718506 30718512

Sources:
CIViC
ABEMACICLIB CCND3

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
ABEMACICLIB CDK6

Interaction Score: 1.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

PMIDs:
24919854

Sources:
ChemblInteractions CancerCommons TTD
ABEMACICLIB CDKN2A

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26183925 27217383

Sources:
ClearityFoundationBiomarkers JAX-CKB OncoKB
ABEMACICLIB CDK4

Interaction Score: 0.91

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

Direct Interaction yes

PMIDs:
24919854

Sources:
ClearityFoundationBiomarkers ChemblInteractions CancerCommons TTD OncoKB
ABEMACICLIB CCND1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
ABEMACICLIB NRAS

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27217383

Sources:
JAX-CKB
ABEMACICLIB KRAS

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Evidence Type Actionable

Approval Status Phase I

PMIDs:
27217383 1291017 26658964

Sources:
JAX-CKB CIViC
ABEMACICLIB PGR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ABEMACICLIB ESR2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ABEMACICLIB ERBB2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ABEMACICLIB ESR1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ABEMACICLIB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Phase I

PMIDs:
27217383

Sources:
JAX-CKB

CancerCommons: LY2835219
- Version: 25-July-2013
Alternate Names:

LY2835219 Drug Trade Name

LY2835219 Drug Development Name

Drug Info:

Drug Class CDK/Rb Inhibitor

Source Reported Drug Name(s) LY2835219

Pharmaceutical Developer Eli Lilly

Publications:

JAX-CKB: Abemaciclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov

von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.

CIViC: ABEMACICLIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov

Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun

Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun

TTD: LY2835219
- Version: 2020.06.01
Alternate Names:

D05SBO TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL3301610
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3301610
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: abemaciclib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: LY2835219
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
OncoKB: Abemaciclib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
FDA: Abemaciclib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Reported Cancer Type	Melanoma
Mechanism of Interaction	Cyclin-dependent kinase 6 inhibitor
Direct Interaction	yes

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive
Approval Status	Phase I

Indication/Tumor Type	non-small cell lung carcinoma
Evidence Type	Actionable
Approval Status	Phase I

Indication/Tumor Type	colorectal cancer
Response Type	sensitive
Approval Status	Phase I

LY2835219	Drug Trade Name
LY2835219	Drug Development Name

ABEMACICLIB Drug Record

ABEMACICLIB chembl:CHEMBL3301610 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30718506 30718512

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor Direct Interaction yes

PMIDs: 24919854

Sources: ChemblInteractions CancerCommons TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type sensitive Approval Status Phase I

PMIDs: 26183925 27217383

Sources: ClearityFoundationBiomarkers JAX-CKB OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor Direct Interaction yes

PMIDs: 24919854

Sources: ClearityFoundationBiomarkers ChemblInteractions CancerCommons TTD OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Phase I

PMIDs: 27217383

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Evidence Type Actionable Approval Status Phase I

PMIDs: 27217383 1291017 26658964

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type sensitive Approval Status Phase I

PMIDs: 27217383

Sources: JAX-CKB

CancerCommons: LY2835219

Alternate Names: LY2835219 Drug Trade Name LY2835219 Drug Development Name

Drug Info: Drug Class CDK/Rb Inhibitor Source Reported Drug Name(s) LY2835219 Pharmaceutical Developer Eli Lilly

Publications:

JAX-CKB: Abemaciclib

Alternate Names:

Drug Info:

CIViC: ABEMACICLIB

Alternate Names:

Drug Info:

TTD: LY2835219

Alternate Names: D05SBO TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL3301610

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3301610

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
30718506 30718512

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

PMIDs:
24919854

Sources:
ChemblInteractions CancerCommons TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26183925 27217383

Sources:
ClearityFoundationBiomarkers JAX-CKB OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

Direct Interaction yes

PMIDs:
24919854

Sources:
ClearityFoundationBiomarkers ChemblInteractions CancerCommons TTD OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27217383

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Evidence Type Actionable

Approval Status Phase I

PMIDs:
27217383 1291017 26658964

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Phase I

PMIDs:
27217383

Sources:
JAX-CKB

Alternate Names:

LY2835219 Drug Trade Name

LY2835219 Drug Development Name

Drug Info:

Drug Class CDK/Rb Inhibitor

Source Reported Drug Name(s) LY2835219

Pharmaceutical Developer Eli Lilly

Alternate Names:

D05SBO TTD Drug ID